Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Fully human monoclonal neutralizing antibody for resisting novel coronavirus and application of fully human monoclonal neutralizing antibody

A monoclonal, antibody technology, used in antiviral agents, antiviral immunoglobulins, applications, etc., can solve the problems of infection risks of other diseases, inability to be widely used, and large differences between batches.

Active Publication Date: 2021-05-14
SUZHOU YUZHIBO BIOLOGICAL TECH CO LTD
View PDF5 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The use of convalescent plasma therapy has shown good therapeutic effects in the treatment of critically ill patients. However, due to limited plasma sources, difficulty in large-scale preparation, large batch-to-batch differences, and the risk of other disease infections, this therapy cannot be used on a large scale. Promoted application of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fully human monoclonal neutralizing antibody for resisting novel coronavirus and application of fully human monoclonal neutralizing antibody
  • Fully human monoclonal neutralizing antibody for resisting novel coronavirus and application of fully human monoclonal neutralizing antibody
  • Fully human monoclonal neutralizing antibody for resisting novel coronavirus and application of fully human monoclonal neutralizing antibody

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0084] Example 1 Screening and preparation of fully human anti-SARS-CoV-2 monoclonal antibody

[0085] 1.1 Labeling of protein probes

[0086] Coupling the required SARS-CoV-2-related specific probes to fluorescent dyes, the process is as follows:

[0087] 1.1.1 Prepare the reaction system according to the instructions of the AviTag Fusion Protein Biotinylation Kit (BirA500, Avidity). Incubate at 30°C for 30 min.

[0088] 1.1.2 Use a 30 kDa ultrafiltration tube to exchange the reaction product with 1× PBS (pH 7.4) to remove excess biotin.

[0089] 1.1.3 Gradually add 1 / 5 molar equivalent of streptavidin-phycoerythrin (SA-PE) or streptavidin-allophycocyanin (SA-APC) to the biotin label at intervals of 20 min in the antigen-specific probe until the molar ratio of SA-PE or SA-APC:biotin-labeled antigen-specific probe reaches 1:1. Incubate with gentle shaking at 4 °C. Fluorescein-labeled probes were thus prepared: Ag(-)-SA-APC and Ag(+)-SA-PE, respectively.

[0090] 1.2 Sepa...

Embodiment 2

[0123] Example 2 Analysis of the binding activity of YK-CoV2-01 antibody to RBD protein

[0124] Antibody-antigen binding activity analysis using Gator label-free biomolecular analyzer

[0125] 2.1. Expression of RBD-chimera using GNTI cells. After being purified by nickel column and molecular sieve sequentially, the RBD chimera was biotinylated according to the steps indicated in the manual of DSB-X™ Biotin Protein Labeling Kit (Invitrogen™).

[0126] 2.2 The biotinylated RBD chimera was diluted 600 times, and 3 μL of the RBD chimera was added to 2000ul HBSEP buffer and mixed. The diluted RBD was loaded into a 96-well sample plate at 200 μL per well.

[0127] 2.3 Use HRV3C enzyme to cut the antibody to be detected into Fab fragments, and use affinity chromatography and molecular sieve to purify the obtained antibody Fab. After diluting the antibody Fab by 1000 times, continue to perform serial dilution according to 1:3, a total of 4 dilutions (36.2nM, 12.1 nM, 4.02 nM and ...

Embodiment 3

[0132] Example 3 Analysis of YK-CoV2-01 Antibody Competitively Blocking the Binding Ability of SARS-CoV2 RBD and Receptor ACE2

[0133] Analysis of Antibody Blocking Binding Ability of SARS-CoV-2 Viral RBD Chimera and Receptor ACE2 Using Gator Non-Labeled Biomolecular Analyzer

[0134] 3.1 Using Expi-CHO cells to express the receptor ACE2. After purification by nickel column and molecular sieve in sequence, ACE2 was biotinylated according to the steps indicated in the manual of DSB-X™ Biotin Protein Labeling Kit (Invitrogen™). The biotinylated ACE2 receptor was diluted to 40ug / ml, and the molar concentration was 570nM.

[0135] 3.2 Dilute RBD to 30 ug / ml, molar concentration 1000 nM. The antibody was diluted to 0.2mg / ml and mixed 1:1 with the RBD chimera. The molar quantity of the antibody in the prepared mixture is greater than the molar quantity of the receptor ACE2.

[0136] 3.3 During the detection process, each experiment is first equilibrated in the HBSEP buffer of t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of biological medicine, and discloses a fully human monoclonal neutralizing antibody for resisting novel coronavirus and application of the fully human monoclonal neutralizing antibody. B-type lymphocytes are screened from blood of a new coronal pneumonia rehabilitation patient, and the affinity constant of the obtained antibody and a virus receptor binding domain (RBD) is 1.19 nM. X-ray crystal diffraction is used for analyzing the three-dimensional structure of the antibody and RBD compound, it is found that the binding epitope of the antibody and the binding epitope of a host cell receptor (ACE2) are highly overlapped, binding of the RBD and the ACE2 can be competitively blocked, and infection of the RBD and the ACE2 is inhibited. The antibody can cope with certain genetic mutations of viruses, the half effective concentration of the antibody for blocking pseudoviruses (accumulated B.1. 1.7 mutant strain genes and D614G) from infecting host cells is 0.57 ng / mL, and the antibody has the advantages of safety, high efficiency and broad spectrum, and is expected to be used as a neutralizing antibody drug for diagnosing, treating and preventing new coronal pneumonia.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a fully human monoclonal neutralizing antibody against novel coronavirus and its application. Background technique [0002] The causative agent of novel coronavirus pneumonia (CoVID-19) is a novel coronavirus (SARS-CoV2), which can cause severe acute respiratory disease. According to the report of the World Health Organization, the epidemic has spread to all parts of the world, causing a large number of casualties. Clinical features of COVID-19 include fever, dry cough and fatigue, respiratory failure, and even death. So far, most of the vaccines and therapeutic drugs against COVID-19 are still in clinical trials and initial emergency trials, and their safety and effectiveness need further verification. [0003] SARS-CoV2 belongs to the genus Coronavirus of the Coronaviridae family, and is a class of enveloped single-stranded positive-sense RNA viruses. The new coronavirus gene enco...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/10C12N15/13A61K39/42A61P31/14G01N33/577G01N33/569
CPCA61P31/14C07K16/10C07K2317/24C07K2317/56C07K2317/565C07K2317/567C07K2317/76C07K2317/92G01N33/56983G01N33/577G01N2333/165G01N2469/10
Inventor 陈磊高腾森戴敏殷建国赵氏璧王聪谢欣张冀周臣飞陈莉周翔宇王得荣
Owner SUZHOU YUZHIBO BIOLOGICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com